- Home
- CIVI vs BLTE Comparison
CIVI vs BLTE Comparison
Compare CIVI & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIVI
- BLTE
- Stock Information
- Founded
- CIVI 1999
- BLTE 2018
- Country
- CIVI United States
- BLTE United States
- Employees
- CIVI N/A
- BLTE N/A
- Industry
- CIVI Oil & Gas Production
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- CIVI Energy
- BLTE Health Care
- Exchange
- CIVI Nasdaq
- BLTE Nasdaq
- Market Cap
- CIVI 3.2B
- BLTE 2.6B
- IPO Year
- CIVI 2011
- BLTE 2022
- Fundamental
- Price
- CIVI $27.60
- BLTE $87.26
- Analyst Decision
- CIVI Buy
- BLTE Strong Buy
- Analyst Count
- CIVI 12
- BLTE 4
- Target Price
- CIVI $43.10
- BLTE $96.00
- AVG Volume (30 Days)
- CIVI 2.7M
- BLTE 63.4K
- Earning Date
- CIVI 11-06-2025
- BLTE 11-11-2025
- Dividend Yield
- CIVI 7.23%
- BLTE N/A
- EPS Growth
- CIVI N/A
- BLTE N/A
- EPS
- CIVI 7.93
- BLTE N/A
- Revenue
- CIVI $4,815,808,000.00
- BLTE N/A
- Revenue This Year
- CIVI N/A
- BLTE N/A
- Revenue Next Year
- CIVI N/A
- BLTE N/A
- P/E Ratio
- CIVI $3.49
- BLTE N/A
- Revenue Growth
- CIVI 0.23
- BLTE N/A
- 52 Week Low
- CIVI $22.79
- BLTE $49.00
- 52 Week High
- CIVI $55.35
- BLTE $91.92
- Technical
- Relative Strength Index (RSI)
- CIVI 34.79
- BLTE 77.78
- Support Level
- CIVI $29.56
- BLTE $78.71
- Resistance Level
- CIVI $34.71
- BLTE $80.19
- Average True Range (ATR)
- CIVI 1.84
- BLTE 2.93
- MACD
- CIVI -0.68
- BLTE 1.06
- Stochastic Oscillator
- CIVI 2.93
- BLTE 81.20
About CIVI Civitas Resources Inc.
Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado - DJ Basin. The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.